Cargando…

Remdesivir vs tocilizumab in COVID-19: adverse event profiles

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379037/ http://dx.doi.org/10.1007/s40278-021-00876-z

Ejemplares similares

Baricitinib + remdesivir cost saving vs remdesivir for hospitalised COVID-19 patients in the USA
Publicado: (2021)

Identification of serious, unpredictable adverse events with tocilizumab
Publicado: (2020)

Benefit-risk assessment for remdesivir in COVID-19
Publicado: (2020)

Cardiac Adverse Events With Remdesivir in COVID-19 Infection
por: Gupta, Anupam K, et al.
Publicado: (2020)

Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients
por: Sarhan, Rania M., et al.
Publicado: (2022)

Remdesivir cost effective for severe COVID-19 in China
Publicado: (2021)

Quality of ADR reporting evaluated for remdesivir trials of COVID-19
Publicado: (2020)

Effects on LOS may not justify cost of remdesivir for severe COVID-19
Publicado: (2021)

Remdesivir does not increase risk of AKI or ALI in COVID-19 patients
Publicado: (2022)

Tocilizumab cost effective in reducing COVID-19-related deaths
Publicado: (2021)

COVID-19 vaccine adverse events reported via app
Publicado: (2021)

CLINICAL EFFECTIVENESS AND ADVERSE EVENTS OF ADJUNCTIVE REMDESIVIR ADMINISTRATION VS STANDARD OF CARE IN ADULTS WITH SEVERE AND CRITICAL COVID-19
por: Viray, D.D., et al.
Publicado: (2023)

Remdesivir may be cost saving in eligible patients during COVID-19 infections in Germany
Publicado: (2021)

Expected rates of adverse events after COVID-19 vaccination in USA
Publicado: (2022)

Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Remdesivir appears to save costs in COVID-19 patients on low-flow oxygen therapy in Turkey
Publicado: (2021)

REMDESIVIR PLUS DEXAMETHASONE VS TOCILIZUMAB OR BARICITINIB SUPPLEMENTATION INITIATED INSIDE 48 HOURS OF INDEX COVID-19 HOSPITALIZATION IN ICU PATIENTS
por: WILLIAMS, STEPHANIE N, et al.
Publicado: (2022)

Remdesivir/tocilizumab: Endogenous endophthalmitis: 3 case reports
Publicado: (2022)

Dexamethasone/remdesivir/tocilizumab: Various toxicities: case report
Publicado: (2022)

Dexamethasone/remdesivir/tocilizumab: Lack of efficacy: case report
Publicado: (2022)

Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment
por: Kelleni, Mina T.
Publicado: (2021)

Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial
por: Rosas, Ivan O., et al.
Publicado: (2021)

Tocilizumab in COVID-19: enthusiasm vs. evidence
por: Zeña-Huancas, Paola, et al.
Publicado: (2021)

Ad26.COV2.S COVID-19 vaccine: TTS a rare, but serious adverse event
Publicado: (2022)

Adverse events following the first, second and third doses of a COVID-19 vaccine in hemodialysis patients
por: Pai, Mei-Fen, et al.
Publicado: (2023)

Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report
por: Witting, Celeste, et al.
Publicado: (2021)

Therapeutic Efficacy and Outcomes of Remdesivir versus Remdesivir with Tocilizumab in Severe SARS-CoV-2 Infection
por: Vulturar, Damiana-Maria, et al.
Publicado: (2022)

Design of the Tocilizumab in Giant Cell Arteritis Trial
por: Unizony, Sebastian H., et al.
Publicado: (2013)

Remdesivir use in severe renal impairment: benefits outweigh risks
Publicado: (2021)

Use of tocilizumab, remdesivir, and high-dose methylprednisolone prevents intubation in an ESRD patient with COVID-19 pneumonia
por: Judge, Ramzan, et al.
Publicado: (2022)

Vaccination-associated cardiac adverse events rare
Publicado: (2022)

Adverse events following remdesivir administration in moderately ill COVID-19 patients - A retrospective analysis
por: Gandham, Ravi, et al.
Publicado: (2022)

Dexamethasone/remdesivir/tocilizumab: Methaemoglobinaemia and off-label use: case report
Publicado: (2021)

Remdesivir/tocilizumab: Lack of efficacy and off-label use: case report
Publicado: (2022)

Implications for Systemic Approaches to COVID-19: Effect Sizes of Remdesivir, Tocilizumab, Melatonin, Vitamin D3, and Meditation
por: Castle, Ryan D, et al.
Publicado: (2021)

551. Remdesivir and Tocilizumab for the Treatment of Severe COVID-19 in a Community Hospital: A Retrospective Cohort Study
por: Rodriguez-Nava, Guillermo, et al.
Publicado: (2021)

Candidemia in COVID‐19 treated with corticosteroids and tocilizumab
por: Yamamoto, Koichiro, et al.
Publicado: (2021)

Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients
por: Hegazy, Sahar Kmal, et al.
Publicado: (2023)

Adverse Events Associated with Methimazole Therapy of Graves' Disease in Children
por: Rivkees, Scott A., et al.
Publicado: (2010)

Frequency of Adverse Events of Antithyroid Drugs Administered during Pregnancy
por: Yoshihara, Ai, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qbto6e38nsddacauntk2qkl02d